Testing a new drug combo for untreated CLL or SLL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests two new oral medications (ICP-248 and Orelabrutinib) together as a first treatment for people with CLL or SLL. The goal is to see if this combination works better than current options and is safe for newly diagnosed patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have not received any prior treatment for your CLL or SLL (except maybe a brief emergency treatment to lower white blood cells).
- You have at least one enlarged lymph node or other sign of disease that can be measured.
- You are in reasonably good health – able to care for yourself and expected to live at least 6 more months.
- You do not have an active serious infection, major heart disease, or a bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
This trial tests a new combination of two targeted drugs (ICP-248 and orelabrutinib) against a single targeted drug (pirtobrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. The goal is to see which approach works better and is safer.
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
This study tests a new treatment schedule that combines the drug orelabrutinib (a targeted therapy) with a fixed-cycle plan, compared with using orelabrutinib alone. This may help people with CLL/SLL who need treatment but haven't had standard therapy yet.
This trial tests a new pill (orelabrutinib) combined with a standard chemotherapy regimen (called BG) as your first treatment for CLL or SLL. The goal is to see if this combination works well and is safe for people like you who have not been treated before.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.